|1.68 0.2 (13.51%)||12-01 15:59|
|Targets||6-month :||2.05||1-year :||2.33|
|Resists||First :||1.76||Second :||2|
|Supports||First :||1.37||Second :||1.14|
|MAs||MA(5) :||1.5||MA(20) :||1.56|
|MA(100) :||2.16||MA(250) :||2.37|
|MACD||MACD :||-0.2||Signal :||-0.2|
|%K %D||K(14,3) :||37||D(3) :||26.7|
|52-week||High :||6.98||Low :||1.29|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENVB ] has closed below upper band by 0.2%. Bollinger Bands are 59.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||1.59 - 1.6||1.6 - 1.6|
|Low:||1.46 - 1.47||1.47 - 1.48|
|Close:||1.47 - 1.48||1.48 - 1.49|
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||2 (M)|
|Shares Float||2 (M)|
|Held by Insiders||12.5 (%)|
|Held by Institutions||10.9 (%)|
|Shares Short||19 (K)|
|Shares Short P.Month||11 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||1.12|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-61.5 %|
|Return on Equity (ttm)||-173.1 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-16 (M)|
|Levered Free Cash Flow||-8 (M)|
|Price to Book value||1.42|
|Price to Sales||0|
|Price to Cash Flow||-0.24|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|